Physician profile
Michael Sy Basuel
NPI 1689652844
$2,716.39
in general payments reported to CMS, 2019-2025
26 companies · $390 in 2025
The $390 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $654 · 2020: $598 · 2021: $402 · 2022: $35.91 · 2023: $105 · 2024: $532 · 2025: $390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $972 · Education: $55.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $971.70 |
| Education | $55.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $332.10 | 2019-2025 | Auryxia, Vafseo |
| Astrazeneca Pharmaceuticals LP | $315.99 | 2019-2024 | Farxiga, Lokelma |
| Mallinckrodt Hospital Products INC. | $240.58 | 2020-2024 | Acthar |
| Otsuka America Pharmaceutical, INC. | $215.98 | 2019-2025 | Jynarque |
| Mallinckrodt Enterprises LLC | $196.57 | 2019 | |
| Vifor Pharma, INC. | $183.69 | 2019-2024 | Veltassa |
| Opko Pharmaceuticals, LLC | $173.02 | 2019-2025 | Rayaldee |
| Fresenius USA Marketing, INC. | $162.37 | 2019-2025 | Velphoro, Velphoro |
| Amgen INC. | $104.76 | 2021-2025 | Tavneos, Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $87.12 | 2021-2024 | |
| Travere Therapeutics, INC. | $80.29 | 2023-2025 | Filspari |
| Calliditas Therapeutics US INC. | $77.86 | 2024-2025 | Tarpeyo |
| Ardelyx, INC. | $63.55 | 2024 | Ibsrela |
| Ani Pharmaceuticals, INC. | $63.03 | 2025 | Purified Cortrophin Gel |
| Lilly USA, LLC | $60.00 | 2023-2025 | Jardiance |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $50.04 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $49.68 | 2019 | |
| Aurinia Pharma U.S., INC. | $49.06 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.62 | 2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $39.29 | 2024-2025 | |
| Horizon Therapeutics Plc | $26.27 | 2019 | |
| Alexion Pharmaceuticals, INC. | $26.14 | 2025 | Ultomiris |
| Alnylam Pharmaceuticals INC. | $23.77 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.05 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $15.21 | 2020 | |
| Shire North American Group INC | $14.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Basuel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.